Company intelligence / Profile preview
Wellington Zhaotai Therapies Limited
Wellington, New Zealandwellingtonzhaotai.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company's lead product WZTL-002 has completed Phase 1 trials (ENABLE-1) for Non-Hodgkin's lymphoma with promising efficacy and improved safety profile compared to existing CAR T-cell treatments. Phase 2 trial (ENABLE-2) is currently recruiting to evaluate efficacy and safety in patients with relapsed or refractory large B-cell lymphoma.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR T-cell therapiesCell therapiesGene therapiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
37 assets36 more assets in the full pipeline.
03
Partnerships
Dr. Reddy's Laboratories Ltd (multi-million dollar commercial deal for exclusive license to CAR T-cell technology in India)BioOra Limited (partnership for automated CAR T-cell manufacture)
Beyond the preview
Go deeper on Wellington Zhaotai Therapies Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wellington Zhaotai Therapies Limited.